Skyrizi 75 mg, lnjektionslösung in einer Fertigspritze

7680669440015 CH-66944 Fertigspritze
Skyrizi 75 mg, lnjektionslösung in einer Fertigspritze
Skyrizi 75 mg, lnjektionslösung in einer Fertigspritze
Skyrizi 75 mg, lnjektionslösung in einer Fertigspritze
1 / 3
google

Article details

Package size
2
Selling units
2
Measure
Fertigspritze(n)
Galenic form
Fertigspritze
Galenic group
unbekannt

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Patient information leaflet
Allemand
21/08/2025
Patient information leaflet
Français
21/08/2025
Patient information leaflet
Italien
21/08/2025
Summary of Product Characteristics
Allemand
21/08/2025
Summary of Product Characteristics
Français
21/08/2025
Summary of Product Characteristics
Italien
21/08/2025

Detailed composition

Substance Quantity Type Category
TEL
- Substance HNIDK
SOLU
75.0 MG Substance Wirkstoff (Principe actif)
SOLU
34.0 MG Substance HBESI
SOLU
- Substance HNIDK
SOLU
0.149 MG Substance HBESI
SOLU
0.149 MG Substance HBESI
SOLU
- Substance HNIDK
SOLU
- Substance HNIDK
SOLU
- Substance HNIDK

Authorization holder

AbbVie AG

6330 Cham

Authorization information

Swissmedic authorization number
66944
Drug name
Skyrizi, lnjektionslösung in einer Fertigspritze
Galenic form
INLFS
ATC Code
L04AC18
Authorization status
Z
Dispensing category
B
First authorization
18/04/2019
Authorization expiration date
31/12/9999
IT Number
07.15.0.
Domain
Human medicine
Field of application
Plaque-Psoriasis bei Erwachsenen, Psoriasis-Arthritis

Package details

Description (FR)
SKYRIZI sol inj 75 mg/0.83ml ser pré 2 pce
Description (DE)
SKYRIZI Inj Lös 75 mg/0.83ml Fertspr 2 Stk
Market launch
18/04/2019
Narcotic (BTM)
No

Other package sizes (1)

SKYRIZI sol inj 150 mg/ml ser pré
1 FESP
GTIN: 7680669440022
View